Can the combination of calcium and parathormone levels above K/DOQI guidelines be used as a marker of adynamic bone disease in African Americans?
- PMID: 20544281
- DOI: 10.1007/s11255-010-9785-9
Can the combination of calcium and parathormone levels above K/DOQI guidelines be used as a marker of adynamic bone disease in African Americans?
Abstract
Background: Patients of African American descent are at risk for the development of adynamic bone disease at parathyroid hormone levels 50% above the K/DOQI guidelines. Since a low bone formation rate is associated with hypercalcemia, attempts to reach one K/DOQI guideline may result in serum calcium levels above another K/DOQI guideline. Calcium levels above K/DOQI guidelines therefore may signal a need to stop parathyroid suppression.
Setting and participants: Bone biopsies were performed at the East Alabama Medical Center, in Opelika AL, USA on eight patients (four Caucasians, four African Americans) whose parathormone levels and serum calcium levels both exceeded K/DOQI guideline recommendations.
Results: All patients had mild to severe hyperparathyroid bone disease. No variable studied was predictive of the finding.
Limitations: Small sample size and the unavailability of the original Nichols Diagnostic Institute radioimmunoassay for parathormone.
Conclusion: We did not find hypercalcemia predictive of adynamic bone in patients of African American descent at levels of parathormone where low bone formation rates have been documented to occur. Since no parameter predicted bone histology, perhaps bone biopsies will be necessary to distinguish hyperparathyroidism from adynamic bone disease in African Americans with ESRD, hypercalcemia, and moderately elevated levels of PTH. Further studies are needed to determine appropriate therapy.
Similar articles
-
Absence of adynamic bone disease in African-Americans with CKD stage 5 after 3 years of vitamin D therapy guided by iPTH and the PTH-(1-84)/N-terminally truncated PTH fragments ratio.Clin Nephrol. 2009 Mar;71(3):267-75. doi: 10.5414/cnp71267. Clin Nephrol. 2009. PMID: 19281737
-
Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.Nephrol Dial Transplant. 2006 Jun;21(6):1663-8. doi: 10.1093/ndt/gfl006. Epub 2006 Feb 7. Nephrol Dial Transplant. 2006. PMID: 16464885
-
[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].Nefrologia. 2008;28 Suppl 3:67-78. Nefrologia. 2008. PMID: 19018742 Spanish.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Bone health and vascular calcification relationships in chronic kidney disease.Int Urol Nephrol. 2007;39(4):1209-16. doi: 10.1007/s11255-007-9276-9. Epub 2007 Sep 26. Int Urol Nephrol. 2007. PMID: 17899431 Review.
Cited by
-
Adynamic bone disorder in chronic kidney disease: meta-analysis and narrative review of potential biomarkers as diagnosis and therapeutic targets.Ren Fail. 2025 Dec;47(1):2530162. doi: 10.1080/0886022X.2025.2530162. Epub 2025 Jul 16. Ren Fail. 2025. PMID: 40669844 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical